Literature DB >> 3265112

Plasminogen activator inhibitor type 1: cell-specific and differentiation-induced expression and regulation in human cell lines, as determined by enzyme-linked immunosorbent assay.

L R Lund1, B Georg, L S Nielsen, M Mayer, K Danø, P A Andreasen.   

Abstract

We have performed a comparative study of the regulation by glucocorticoids and phorbol 12-myristate 13-acetate (PMA) of the production of type 1 plasminogen activator inhibitor (PAI-1) by 12 human cell lines. A sandwich-type enzyme-linked immunosorbent assay (ELISA) for PAI-1 that measures free PAI-1 as well as complexes between PAI-1 and both types of plasminogen activators has been used. Basal PAI-1 accumulation varied more than 5000-fold between the cell lines. No correlation was found between the PAI-1 level and other characteristics of the cell lines, except that three lines of SV40-transformed fibroblasts produced more PAI-1 than two non-transformed fibroblast cell lines. Three out of the 12 cell lines responded to glucocorticoids by an increased PAI-1 production. Four cell lines responded to PMA by an increased PAI-1 production. In addition, PMA-induced differentiation of the monocyte cell line U937 and the promyelocytic cell line HL-60 into macrophage-like cells was found to be correlated with an up to 100-fold increase in PAI-1 accumulation. The PMA-dependent differentiation of HL-60 cells led to acquisition of glucocorticoid inducibility of PAI-1. These findings provide information for future studies of the molecular mechanism of cell-specific expression and regulation of PAI-1.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3265112     DOI: 10.1016/0303-7207(88)90118-9

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  7 in total

1.  Targeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodies.

Authors:  Kenneth A Botkjaer; Sarah Fogh; Erin C Bekes; Zhuo Chen; Grant E Blouse; Janni M Jensen; Kim K Mortensen; Mingdong Huang; Elena Deryugina; James P Quigley; Paul J Declerck; Peter A Andreasen
Journal:  Biochem J       Date:  2011-08-15       Impact factor: 3.857

2.  Prourokinase activation on the surface of human rhabdomyosarcoma cells: localization and inactivation of newly formed urokinase-type plasminogen activator by recombinant class 2 plasminogen activator inhibitor.

Authors:  J Pöllänen; A Vaheri; H Tapiovaara; E Riley; K Bertram; G Woodrow; R W Stephens
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

3.  Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor.

Authors:  M V Cubellis; P Andreasen; P Ragno; M Mayer; K Danø; F Blasi
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

4.  A novel mode of intervention with serine protease activity: targeting zymogen activation.

Authors:  Grant E Blouse; Kenneth A Bøtkjaer; Elena Deryugina; Aleksandra A Byszuk; Janni M Jensen; Kim K Mortensen; James P Quigley; Peter A Andreasen
Journal:  J Biol Chem       Date:  2008-12-01       Impact factor: 5.157

5.  Lysosomal degradation of receptor-bound urokinase-type plasminogen activator is enhanced by its inhibitors in human trophoblastic choriocarcinoma cells.

Authors:  P H Jensen; E I Christensen; P Ebbesen; J Gliemann; P A Andreasen
Journal:  Cell Regul       Date:  1990-12

6.  Urokinase-receptor biosynthesis, mRNA level and gene transcription are increased by transforming growth factor beta 1 in human A549 lung carcinoma cells.

Authors:  L R Lund; J Rømer; E Rønne; V Ellis; F Blasi; K Danø
Journal:  EMBO J       Date:  1991-11       Impact factor: 11.598

7.  Resveratrol suppresses PAI-1 gene expression in a human in vitro model of inflamed adipose tissue.

Authors:  Ivana Zagotta; Elitsa Y Dimova; Jan-Bernd Funcke; Martin Wabitsch; Thomas Kietzmann; Pamela Fischer-Posovszky
Journal:  Oxid Med Cell Longev       Date:  2013-06-02       Impact factor: 6.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.